Case Crossover Study of PDE5 Inhibitor Exposure as a Potential 'Trigger Factor' for Acute NAION.
Phase of Trial: Phase IV
Latest Information Update: 16 Oct 2013
At a glance
- Drugs Sildenafil; Tadalafil; Vardenafil
- Indications Benign prostatic hyperplasia; Erectile dysfunction
- Focus Adverse reactions
- Sponsors Pfizer
- 01 Oct 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 29 Nov 2011 Planned end date changed from 1 Nov 2011 to 1 Nov 2012 as reported by ClinicalTrials.gov.
- 06 Sep 2011 Planned end date changed from 1 Nov 2012 to 1 Nov 2011 as reported by ClinicalTrials.gov.